Oncolys BioPharma: Confirmation
Oncolys BioPharma: Quarterly Report - 21st Quarter 1st Quarter (2024/01/01 to 2024/03/31)
Oncolys BioPharma: Summary of Financial Results for the 1st Quarter Ending 2024/12 [Japanese GAAP] (Unconsolidated)
Daiwa House, Meiji HD, Shiseido, Sumitomo Electric (10th) (1301-5998)
*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/10 (Fri) <1301>Kyokuyo <1379>Hokuto <1414>Show Bond <1420>Sanyo H<1429>Japan Aqua <1431>Ribwork<1435>Robot Home <1438>Gifu Landscaping<1
Kyom, TORICO, etc.
<2385>Establishing an industry-academia collaboration course and signing a joint research agreement with General Medical Research Institute Tokyo Jikei University <3557>Number of shares issued from mass exercise of U&C 9th Stock Acquisition Rights (with exercise price correction clauses) from the 6th, 50,000 shares <3998>Business Alliance with Surara Net Withers <9696> <4583 Kiom CT-701 license agreement terminated with ADC Therapeutics due to the transition of clinical trial subjects to NCI <4588>Oncolis Bio 19th Stock Acquisition Rights (
Brands that moved the day before part 2 Graphico, Sakura KCS, Colombia, etc.
<コード>Stock name 29th closing price ⇒ NYK Line <9101> 4073-77 shipping stock compared to the previous day is being pushed by a soft trend. Capcom <9697> 2795-31JP Morgan Securities lowered its target stock price. Renesas Electronics<6723> 2670.5 -13.5 TOPIX rebalance round also had a heavy increase in price. Mitsui Chemicals <4183> is it a rebalance sale with awareness of the weight of the value above 4331 -95? Cookpad <2193> 185 +50 large-scale self
Front market [stocks that have moved, stocks that have been created]
*Koito Seisakusho <7276> 2535 Ka - In anticipation of an improvement in supply and demand due to the announcement of a high level of share buybacks. *A new purchase is recommended at KOKUSAI ELECTRIC <6525> 4215 +370 Mizuho Securities. *Sega Sammy HD <6460> 2018 +151.5 Additional structural reform measures announced. *I-NET <9600> 2458 +183 The search for data center-related stocks is expanding. *Profit from sale of Fuji HD <4676> 1965 +136 investment securities
Volume change rate ranking (10:00) ~ Ichigo, Birdman, etc. are ranked
* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [as of 3/29 10:33] (Last 5 Day Average Volume Comparison) Stock Code Stock Name Volume 5 Day Average Volume Volume Change Rate Stock Price Change Rate <7063> Birdman 339200 14615.68 343.48% 0.244
Volume change rate ranking (13:00) ~ Oncolis, Ascot, etc. are ranked
* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [as of 3/28 13:32] (Last 5 Day Average Volume Comparison) Code ⇒ Stock ⇒ Volume ⇒ 5 Day Average Volume ⇒ Volume Change Ratio ⇒ Stock Price Change Ratio <3929> Social Wire 205200 18900 269.99% 0.0038% <2164> Regional Newspapers
Is the weak trend, depreciation of US stocks, etc. heavy, but the lower price is a steady development
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to develop softly. In the US stock market yesterday 26th, the Dow Average continued to fall slightly for 3 days to 39282.33 dollars, which depreciated by 31.31 dollars (-0.08%). It rose after being close to purchases in response to expectations of interest rate cuts. Expectations for a soft landing were also supported, and the market price remained generally steady, but towards the end of the month, it began to decline due to adjustments related to the end of the month and the end of the fiscal year. Today's emerging markets are likely to be dominated by sales. Major indices in the US stock market yesterday
Oncolys BioPharma FY Parent Loss Y1.94B Vs Loss Y1.15B
Oncolys BioPharma Inc. (4588.TO) Japan Year Ended December 31 PARENT 2023 2022 Revenue Y63.00 mln Y976.00 mln Operating Profit (Y1.93 bln)
Oncolys BioPharma Sees FY Parent Pretax Loss Y1.78B
PARENT New Forecast For Year to Dec 2023 Revenue Y63.00 mln Operating Profit (Y1.81 bln) Pretax Profit (Y1.78 bln)
Oncolys BioPharma 9-Mos Parent Loss Y1.27B Vs Loss Y835.00M
Oncolys BioPharma Inc. (4588.TO) Japan Nine Months Ended September 30 PARENT 2023 2022 Revenue Y63.00 mln Y784.00 mln Operating Profit (Y
Oncolys BioPharma 1H Parent Loss Y868.00M Vs Loss Y570.00M
Oncolys BioPharma Inc. (4588.TO) Japan 1st Half Ended June 30 PARENT 2023 2022 Revenue Y63.00 mln Y426.00 mln Operating Profit (Y900.
Oncolys Biopharma Partner Enrolls First Patient in Phase IIa Study of Aicardi-Goutières Syndrome Drug
Japanese biopharma company Oncolys Biopharma (TYO:4588) said that Transposon Therapeutics, the licensee of OBP-601, has enrolled the first patient in the Phase IIa, open-label study of patients with A
Oncolys BioPharma FY Parent Loss Y1.15B Vs Loss Y1.62B
Oncolys BioPharma Inc. (4588.TO) Japan Year Ended December 31 PARENT 2022 2021 Revenue Y976.00 mln Y642.00 mln Operating Profit (Y1.20 b
No Data